Popow-Kraupp T, Kundi M, Ambrosch F, Vanura H, Kunz C
J Med Virol. 1986 Jan;18(1):69-79. doi: 10.1002/jmv.1890180109.
A prospective, randomised clinical trial was conducted to evaluate the efficacy of two live attenuated mumps-measles vaccines, the Urabe Am 9-Schwarz and the Jeryl Lynn-Moraten vaccine, in 400 young children aged 9 months-4.5 years (median 13.4 months). Antibody responses to both vaccine components were measured by the enzyme-linked immunosorbent assay (ELISA); 96.9% of the seronegative children who received the Urabe Am 9-Schwarz vaccine showed satisfactory mumps antibody responses compared to 90% of the Jeryl Lynn-Moraten vaccine recipients (P less than .01). Similar proportions of both groups, 98.5% and 96.8%, respectively, developed measles virus specific antibodies. Both vaccines were equally well tolerated and clinically acceptable.
开展了一项前瞻性随机临床试验，以评估两种减毒活腮腺炎-麻疹疫苗（Urabe Am 9-Schwarz疫苗和Jeryl Lynn-Moraten疫苗）对400名9个月至4.5岁（中位数13.4个月）幼儿的疗效。通过酶联免疫吸附测定（ELISA）检测对两种疫苗成分的抗体反应；接种Urabe Am 9-Schwarz疫苗的血清阴性儿童中，96.9%表现出令人满意的腮腺炎抗体反应，而接种Jeryl Lynn-Moraten疫苗的儿童这一比例为90%（P<0.01）。两组中分别有98.5%和96.8%的儿童产生了麻疹病毒特异性抗体。两种疫苗的耐受性均良好，且在临床上均可接受。
